Rare Benign Lesion of Peins
Pseudoepitheliomatous Hyperplasia of the Penis a Very Rare Disease in Egypt
Pseudoepitheliomatous Hyperplasia of the Penis a Very Rare Disease in Egypt
Sponsor study identifier
observational
1
1 country
1
Study Start
January 12, 2021
Actual (reported)Primary Completion
January 12, 2021
Actual (reported)Study Completion
January 12, 2021
Actual (reported)PEKMB was first named and described by Lortat-Jacob \& Civatte in 1961 and by Bart \& Kopf later. This rare condition is mostly reported in elderly males. The keratotic scales is usually micaceous and resembles psoriasis. Most patients are above 50 years of age and are circumcised later in life, but also reported in younger age group. This mica like scales contains keratin which gets dissolved in 10% potassium hydroxide solution. Disease progression may lead to phimosis. Differential diagnosis of this disease entity include moniliasis, wart, psoriasis ,penile horn, circinate balanitis, erythroplasia of Queyrat, squamous cell epithelioma and verrucous carcinoma. It is primarily a benign entity, it is capable of invasiveness. Bart and Kopf considered it to be in intermediate stage between benign hyperplasia and squamous cell carcinoma. However, the histological spectrum can range from hypertrophic-hyperplastic penile dystrophy to verrucous carcinoma. Fibro sarcoma has been reported developing in a same patient. Etiology is unclear. Despite search for a viral agent, Human Papilloma Virus (HPV) has not been demonstrated and its role in pathogenesis or its transformation to verrucous carcinoma has been proved. The treatment of PEKMB should be conservative when there is no histological evidence of malignancy. All such patients should be followed up. Treatment choices include potent topical steroids, topical 5% 5-flurouracil cream1, 2, cryotherapy, radiotherapy and shaving biopsy plus electro coagulation. When frank malignancy is observed, excision with wide margin is the rule.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 12, 2021
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 12, 2021
Actual (reported)January 12, 2021
Actual (reported)January 12, 2021
Actual (reported)January 16, 2021
Actual (reported)January 26, 2021
Actual (reported)improvement of the skin lesion
drugs will be given to patient then the effect ,either improvement or worsening will be noticied
1 month after treatment
improvement of associated lesion
patient complained of difficulty and burning micturition which will be seen after treatment
1 month after drug given
male healthy married
Assuit Medical School
Asyut, Assuit, 71621, Egypt
1 participants (actual enrollment reported by the registry).
First Submitted
January 16, 2021
First Posted
January 26, 2021
Study Start
January 12, 2021
Actual (reported)Economic Evaluation in Teledermatology
Contact the study team to confirm eligibility.
Primary Completion
January 12, 2021
Actual (reported)Study Completion
January 12, 2021
Actual (reported)Last Updated
January 26, 2021
Record last verified: 2021-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: